Kate Rochlin

Kate has served as the Chief Operating Officer since December 2021. She previously served as the VP and AVP of Operations and Innovation since August 2020. She has over 15 years of extensive expertise in early-stage biotechnology and company development, including conducting scientific research, managing intellectual property (IP) strategy, overseeing strategic & business development, and managing company operations including corporate strategy, partnering, and team buildout. She joined Curadigm, a Cambridge, MA-based biotechnology company where she held various senior roles, most recently as Chief Business Officer. She helped lead Curadigm’s spin-out from Nanobiotix and developed collaborations and partnerships around a novel platform to increase therapeutic bioavailability. Crain’s New York Business recognized Kate as one of the top women in tech in 2019. Previously, she served as the Director of Scientific Affairs at Filament BioSolutions, developing therapeutics in oncology supportive care, specifically for oral mucositis. She is a scientific and business advisor to Immunovent, a New York-based biotechnology company she co-founded and previously served as its Chief Scientific Officer. Dr. Rochlin also serves as an executive board member to The Solution Lab, a New York-based non-profit organization dedicated to providing Ph.D. and MBA students with real-world consulting experiences.

Dr. Rochlin earned a Ph.D. in Molecular Biology and Genetics from Weill Cornell Medical College, conducting research at Sloan Kettering Institute, and a BA in Biology from the University of Pennsylvania.